Author Topic: (Abst.) Efficacy and tolerability of medicinal cannabinoids in patients w/MS  (Read 110 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9816
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, January 16, 2019--"Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis:  A systematic review and meta-analysis":


https://www.ncbi.nlm.nih.gov/pubmed/30646241

MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9816
  • MS diagnosed 1980
  • Location: Pacific Northwest
The same issue of JAMA Network Open (October 5, 2018) contains this article--"Cannabinoids for symptoms of multiple sclerosis:  Benefits still unclear":


https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2706491
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
142 Views
Last post June 27, 2017, 03:52:35 pm
by agate
0 Replies
85 Views
Last post November 17, 2017, 09:11:56 pm
by agate
0 Replies
113 Views
Last post May 04, 2018, 02:21:14 pm
by agate
0 Replies
177 Views
Last post June 16, 2018, 02:56:04 pm
by agate
2 Replies
218 Views
Last post September 08, 2019, 04:17:59 pm
by agate